Uppsala, Sweden, 2018-04-23, In accordance with the decision of the Annual General Meeting of Biovica International AB on August 31st, 2017, the Nomination Committee shall consist of three members, representing the two shareholders with the highest number of shares willing to be included in the Nomination Committee, and the Chairman of the Board. The Nomination Committee then elects the chairman.
Biovicas VD Anders Rylander kommenterar bolagets andra delårsrapport 2017/2018. Han berättar bla mer om bröstcancerstudien som presenterades på San Antonio konferensen i början av december tillsammans med forskare på Lund universitet, artikeln i Breast Cancer Research and Treatment tillsammans med Washington University, artikeln i tidskriften Pancreas, ny Operations manager och milstolparna under 2018. [...]
Uppsala, Sweden, November 8, 2017. Mattias Bergqvist, VP Clinical Development at Biovica is invited to talk at the 13th Annual Biomarkers Congress 15-16 February 2018, Manchester, UK. As part of the congress Mattias will present at a free webinar on November 28, 2017.
Uppsala, Sweden, November 6. 2017. The Facebook Group " Aktier – Småbolagsjakten " organizes a live QA session with Biovica International's CEO Anders Rylander on November 20, 2017 between 19.00 - 20.00.
Biovicas VD Anders Rylander sammanfattar inledningsvis det första kvartalet i bolagets brutna räkenskapsår 2017/18. Därefter svarar han på frågor om de personalrekryteringar som har gjorts under kvartalet, förklarar hur tekniken DiviTum fungerar samt standardplattformen ELISA, vilka regulatoriska godkännanden som behövs för produkten på några nyckelmarknader, samt berättar avslutningsvis om Biovicas strategi fram till 2019. [...]
Biovica's CEO Anders Rylander summarizes the first quarter of the company's fiscal year 2017/18. The interview focuses on the latest recruitments that have been made during the quarter, the DiviTum technology, and regulatory approvals needed for the product in key markets. The interview ends with Anders Rylander commenting on the Biovica strategy until 2019. [...]
Uppsala, Sweden, May 22 2017. Samuel Rotstein has been appointed as Scientific Advisor to Biovica.
Uppsala 9 maj 2017. Biovica har erhållit nytt patent i Kina samt patentförlängning för bolagets tekniknologi i USA. Båda patenten avser Biovicas metod för att mäta tymidinkinas-aktivitet på en realtids-PCR-plattform. Det kinesiska patentet gäller till och 13:e maj 2031. Det amerikanska patentet har godkänts sedan tidigare men erhåller nu en förlängning med 430 dagar, [...]
Uppsala, Sweden May 9 2017. Biovica has received a new patent in China as well as patent extension for the company's technology in the United States. Both of the patents refer to Biovica's method of measuring thymidine kinase activity on a real-time PCR platform. The Chinese patent is valid until 13 May 2031. The U.S. patent [...]
Biovica will attend the ASCO (American Society of Clinical Oncology) Annual Meeting, an event that brings together 30 000 global oncology professionals. During ASCO Biovica will meet Pharma companies and oncologists to share the latest insights from the ongoing clinical trial programme and collaborations. Biovica has also been invited to present the latest DiviTum® data at [...]
Follow Biovica